University spinouts have long been engines of breakthrough innovation. But in MedTech, great science is only the starting point. What determines success is whether that science can be translated into a product that works in the real world, passes regulation, and gets adopted by clinicians.

At Maddison, this is not theory. It is lived experience.

David Maddison was there at the beginning of the UK spinout ecosystem, working alongside pioneers such as Tom Hockaday (former Managing Director of Oxford University Innovation, one of the UK’s leading university commercialisation offices) and David Baghurst (a key figure in UK technology transfer and innovation, supporting the translation of academic research into commercial ventures). Over four decades, he has helped turn academic breakthroughs into commercially viable medical technologies.

That journey has included collaborations with institutions such as University College London, Imperial College London, University of Cambridge, and University of Manchester, as well as organisations like the Design Council and SETsquared Partnership.

The result is a clear, repeatable truth.

Spinouts succeed when they follow a disciplined pathway, not when they rely on science alone.

Below is that pathway.

Stage 0, Concept and Intellectual Property

Protect it before you promote it

Every spinout starts in the lab. Most fail here without realising it.

The biggest mistake is publishing too early. Once disclosed, your idea may no longer be patentable.

At this stage:

• Lock down your invention with proper documentation
• Engage your Technology Transfer Office early
• Run a Freedom to Operate assessment
• Validate that a real clinical problem exists

This is where commercial thinking must begin. Not later.

Stage 1, Feasibility and Prototype

Demo or die

Ideas do not attract investment. Prototypes do.

The faster you can build something tangible, the faster you increase value and reduce dilution.

Key priorities:

• Rapid, low cost prototyping
• Early testing against clinical benchmarks
• Risk management aligned with ISO 14971
• Initial regulatory classification via Medicines and Healthcare products Regulatory Agency

Funding often comes from sources like Innovate UK or university seed programmes.

At the end of this stage, you need one thing.

A working prototype that proves the concept.

Stage 2, Spinout Formation

From project to company

This is where most academic teams underestimate the shift required.

You are no longer running a research project. You are building a business.

Key moves:

• Incorporate a UK Ltd company
• Agree IP licensing or assignment with the university
• Build a team beyond science, clinical, regulatory, commercial
• Develop a credible, investor ready business plan

This is where clarity matters. Investors do not fund potential. They fund direction.

Stage 3, Regulatory and Clinical Strategy

Regulation is not a hurdle, it is the roadmap

Too many teams treat regulation as a late stage problem. That is a costly mistake.

It should shape development from the outset.

Key actions:

• Implement ISO 13485 quality systems
• Engage early with the Medicines and Healthcare products Regulatory Agency
• Build a clinical evaluation strategy
• Define health economics, how this saves money or improves outcomes

Funding here often comes from National Institute for Health and Care Research programmes, angels, and early venture capital.

At this point, you are no longer proving the idea.

You are proving it can become a product.

Stage 4, Clinical Trials and Approval

Where risk becomes real

This is the most expensive and high risk phase.

By now, you will have investors. You will also have dilution.

The only question is how much.

Key priorities:

• Conduct clinical trials with regulatory and NHS approval
• Build full technical documentation
• Secure approvals such as CE marking or FDA clearance

The earlier you de risked the programme, the stronger your position now.

Stage 5, Manufacturing and Market Launch

From invention to adoption

Approval is not the finish line. It is the starting point for commercial reality.

This stage requires a fundamental shift.

From inventor to operator.

Key actions:

• Secure GMP compliant manufacturing
• Build supply chains and quality systems
• Define distribution and route to market
• Implement post market surveillance

This is where many technically strong companies fail. Not because the product does not work, but because the system around it does not.

What 40 Years Teaches You

Across projects like Smart Liver at UCL, capsule endoscopy at QMUL, and diagnostics platforms from Leeds to Glasgow, one pattern is clear.

The winners move early, move lean, and stay commercially focused from day one.

They:

• Protect IP before publishing
• Prototype quickly
• Build with regulation in mind
• Think about reimbursement early
• Treat design as a commercial tool, not an aesthetic layer

Final Thought

Spinning out a medical device is not just about innovation.

It is about translation.

Turning complex science into something investors understand, regulators approve, clinicians trust, and patients benefit from.

That requires discipline.

It requires speed.

And above all, it requires a mindset.

Demo or die.